Off-Label Use of Dexmedetomidine for the Treatment of Delirium in the Intensive Care Unit
- PMID: 27757003
- PMCID: PMC5047002
Off-Label Use of Dexmedetomidine for the Treatment of Delirium in the Intensive Care Unit
Abstract
Objective: Evaluate recent clinical studies involving the use of dexmedetomidine (DEX) infusion for the treatment of delirium in the intensive care unit (ICU).
Methods: A literature search was conducted to identify peer-reviewed articles in MEDLINE (1966-June 2016) using the terms sedation, analgesic, dexmedetomidine, delirium, and critically ill adult patients.
Results: Two studies in the ICU setting reported the potential benefits of DEX for managing agitation during weaning from mechanical ventilation. One pilot study and a clinical trial reported the use of DEX in the treatment of ICU delirium.
Conclusion: Further studies are required to evaluate the use of DEX treatment in critically ill patients presenting with delirium.
Keywords: critically ill patients; delirium; dexmedetomidine.
References
-
- Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41:263–306. - PubMed
-
- Dubois MJ, Bergeron N, Dumont M, et al. Delirium in an intensive care unit: a study of risk factors. Intensive Care Med. 2001;27:1297–1304. - PubMed
-
- Pandharipande PP, Shintani A, Perterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006;104:21–26. - PubMed
-
- Ely EW, Shintani A, Truman B. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291:1753–1762. - PubMed
LinkOut - more resources
Full Text Sources